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Abstract
Chimeric antigen receptor (CAR) T cell therapy has been acclaimed as a revolution in cancer 
treatment following the impressive results in hematological malignancies. Unfortunately, in 
patients with solid tumors, objectives responses to CAR T cells are still anecdotal, and important 
issues are driven by on-target but off-tumor activity of CAR T cells and by the extremely complex 
biology of solid tumors. Here, we will review the recent attempts to challenge the therapeutic 
impediments to CAR T cell therapy in solid tumors. We will focus on the most promising 
strategies of antigen targeting to improve tumor specificity and address the tumor heterogeneity, 
efforts to circumvent the physical barriers of the tumor architecture such as subverted tumor 
vasculature, impediments of CAR T cell trafficking and immune suppressive microenvironment.
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INTRODUCTION
Chimeric antigen receptors (CARs) are antigen receptors resulting from the fusion of a 
single-chain variable fragment (scFv) of a monoclonal antibody (mAb) with the ζ-chain of 
the T cell receptor complex and one or two costimulatory moieties(1–3). Upon expression in 
T cells, CARs allow Major Histocompatibility Complex (MHC)-unrestricted recognition of 
surface antigens expressed by tumor cells, T cell activation, proliferation and tumor 
cytolysis. MHC-unrestricted antigen recognition of CAR T cells overcomes the 
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downregulation of Human Leucocyte Antigen molecules frequently orchestrated by cancer 
cells to escape immune recognition, while the scFv-mediated antigen recognition enables T 
cells to target also non-protein epitopes, widening the repertoire of actionable targets in 
cancer immunotherapy, and expanding the potentials of adoptive cell therapy in solid tumors 
pioneered by the use of tumor infiltrating lymphocytes (TILs) in melanoma(4). As briefly 
summarized in Table 1, CAR T cells may have several strengths as compared to TILs for the 
treatment of solid tumors. Although CAR T cells have been a clinical breakthrough in some 
hematologic malignancies(5–7), the development of such strategy for solid tumors is still in 
its infancy. As illustrated in Table 2, objective responses in patients with solid tumors treated 
with CAR T cells are scant, whereas on-target but off-tumor toxicities remain a great 
concern(8–32). The modest activity of CAR T cells in solid tumors as compared to B cell 
malignancies can be largely attributed to the intrinsic biologic differences between the two 
cancerous entities. Extreme heterogeneity of antigen expression and antigen-sharing with 
vital organs, presence of physical barriers for immune cell trafficking and penetration, 
together with the development of an immune suppressive microenvironment are general 
features of most of the non-hematological malignancies. In the present article, we provide a 
concise overview of the approaches that have been implemented to adapt CAR T cells to the 
complex pathophysiology of solid tumors taking particular attention to the strategies that are 
reaching the clinical investigation.
IDENTIFICATION OF TARGETABLE ANTIGENS IN SOLID TUMORS
On-target but off-tumor activity
The success of CAR T cells targeting the pan-B cell marker CD19 in B-cell malignancies 
was predicated on the tolerability of the protracted B-cell aplasia caused by the sustained 
persistence of CAR T cells(7). In sharp contrast, the development of CAR T cells targeting 
solid tumors has been hampered by the anticipated and intolerable toxicity that can be 
caused by CAR T cells targeting antigens expressed by tumor cells but shared with normal 
tissues. Severe toxicities caused by on-target but off-tumor antigen recognition by CAR T 
cells have been reported in clinical studies. In a phase I study of anti-CAIX CAR T cells in 
metastatic renal cell carcinoma, the expression of CAIX on the bile duct epithelial cells 
caused dose-limiting liver toxicity(12). In a second study, the infusion of CAR T cells 
targeting HER2 caused fatal acute respiratory distress syndrome due to recognition of lung 
epithelia cells expressing low levels of HER2(10). It remains an open question if antigens 
overexpressed on the cell surface of tumor cells in solid tumors and at low levels in some 
normal tissues can be safely targeted by CAR T cells. Some clinical data and preclinical 
models suggest that a therapeutic window may be achievable taking in consideration which 
antigen epitopes are targeted by CAR T cells, the density of antigen expression and the 
affinity of the scFvs used to generate CARs. For example, HER2-specific CAR T cells 
targeting different epitopes can significantly reduce the activity of CAR T cells in normal 
tissues without compromising tumor recognition likely due to different accessibility to the 
epitope by the scFv in normal tissue as compared to cancerous cells(14). Preclinical 
observations suggest that higher antigen density expression in the tumor as compared to 
normal tissues can be exploited to effectively eliminate tumor cells, while sparing normal 
cells(33,34). Similarly, tuning the affinity of scFvs may also preferentially trigger CARs 
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upon binding to tumor cells expressing high levels of the antigen, sparing normal cells 
expressing physiologic levels of the antigen, as preclinically showed for both HER2 and 
EGFR(35,36). Solid tumors can express aberrant splicing isoforms and molecules 
characterized by subverted protein glycosylation, thus targeting tumor-specific splicing 
variants or tumor-specific glycosylation sites represents another strategy to overcome on-
target but off-tumor activity in solid tumors(28,37,38). In order to increase the tumor 
specificity, CAR T cells can also be engineered to express combinatorial antigen-sensing 
systems that trigger T cell activation only when two tumor-specific antigens are 
simultaneously present on the cell surface, as in the case of the integration of combinatorial 
targeting and splitting signal [38] or ON-switch strategies (39,40).
Heterogeneity of antigen expression in solid tumors
The second critical aspect of the identification of targetable antigens in solid tumors 
concerns the high heterogeneity of antigen expression at both intra and intertumoral level 
leading to tumor escape due to both antigen loss and clonal evolution. Targeting more than 
one antigen already represents the next generation CAR T cells in B-cell malignancies upon 
the evidence that both leukemia and lymphoma cells can lose the expression of the CD19 
targeted epitope after treatment with CD19-specific CAR T cells(41). Consistently, CAR T 
cells engineered to recognize multiple antigens in solid tumors such as EGFR, HER2 and 
IL13Rα2 have been tested in pre-clinical models(42). Alternatively, CAR T cells can be 
combined with epigenetic drugs that can upregulate the expression of target antigens, as 
reported for GD2 upregulation in Ewing Sarcoma upon pharmacological inhibition of 
EZH2(43).
OVERCOME PHYSICAL BARRIERS IN SOLID TUMORS
Immune cell trafficking and infiltration of peripheral tissues is regulated by a complex 
signaling network and physical processes, which are significantly subverted in tumors. 
Tumor blood vessels are characterized by abnormalities in endothelial junctions and 
expression of adhesion and extravasation molecules that limit an efficient T cell 
recruitment(44). Moreover, the chemokine network orchestrating immune cell migration and 
the stroma including fibroblasts and myeloid cells are highly dysregulated in solid tumors 
further impairing the access of T cells within the tumor bed(45).
Local delivery of CAR T cells
Local drug delivery is one of the most exploited strategy to overcome biological barriers in 
solid tumors especially in malignancies characterized by locoregional aggressiveness (Figure 
1, panel A). Local CAR T cell delivery in solid tumors in addition to maximizing the 
accumulation of CAR T cells at the tumor site, may also improve the safety profile, limiting 
their systemic biodistribution and, consequently, the access to vital organs sharing the 
expression of targeted antigens. Brain tumors are a typical example where local CAR T cell 
delivery has high clinical potential. Complete tumor regression was reported in a patient 
with highly aggressive recurrent glioblastoma with multifocal leptomeningeal disease upon 
infusion of anti-IL13Rα2 CAR T cells into the resected tumor cavity and into the ventricular 
Fucà et al. Page 3













system(19). Intracranial delivery of CAR T cells was effective also in a mouse model of 
HER2+ breast cancer with brain metastasis(46).
Malignancies with a pleural or peritoneal spreading are also particularly attractive for the 
local delivery of CAR T cells. As a proof of concept, intravenous injection of anti-MUC1 
CAR T cells caused their redistribution mainly to the liver and spleen, with a trafficking 
circuit comprising axillary, retroperitoneal and popliteal lymph nodes, but with modest 
localization in the peritoneal cavity(47). In contrast, CAR T cells infused intraperitoneally 
localized and persisted throughout the peritoneal cavity with limited extraperitoneal 
distribution causing improved antitumor activity in mouse models of colorectal cancer 
peritoneal carcinomatosis and ovarian cancer as compared to systemic 
administration(33,48). Liver-limited metastatic disease is another interesting setting for local 
delivery of CAR T cells. In a phase I clinical trial, anti-CEA CAR T cells delivered through 
percutaneous hepatic artery infusion in 5 patients with CEA-positive colorectal cancer liver 
metastases were safe and promoted sustained stabilization of disease in one patient(15). 
Other proof-of-concept clinical studies with promising data of antitumor activity were 
conducted with locally delivered anti-cMET CAR T cells in patients with metastatic breast 
cancer and with anti-mesothelin CAR T cells administered intrapleurally in patients with 
primary malignant pleural mesothelioma or secondary metastatic disease(29,49). In line with 
the effort to develop local delivery of CAR T cells is the parallel development of implantable 
biomaterials to manipulate cell and tissue properties and to enhance persistence of locally 
delivered cells (Figure 1, panel B). Encapsulating or embedding CAR T cells in implantable 
biopolymer scaffolds resulted in a better persistence and antitumor effects in mouse models 
of pancreatic cancer and melanoma(50). Furthermore, biopolymer scaffolds can not only 
accommodate cells but also be loaded with costimulatory molecules, cytokines and small 
molecules that can further enhance the antitumor activity of CAR T cells or target the 
TME(50).
Overcome the subverted tumor vasculature
The first obstacle for CAR T cells in reaching the tumor bed upon intravenous infusion is 
represented by the subverted tumor blood and lymphatic vasculature. To overcome the 
aberrant tumor vasculature, CAR T cells can be combined with antiangiogenic drugs in the 
effort of normalizing the intratumoral blood flow (Figure 1, panel C). Administration of the 
anti-VEGF agent bevacizumab boosted the tumor infiltration and anti-tumor activity of CAR 
T cells targeting the GD2 antigen in an orthotopic xenograft model of neuroblastoma(51). 
Similarly, sub pharmacologic concentrations of the tyrosine-kinase inhibitor with anti-
VEGFR activity sorafenib enhanced the infiltration and antitumor activity of CAR T cells 
targeting GPC3 in a mouse model of hepatocellular carcinoma(52). In contrast, 
pharmacologic concentrations of sorafenib showed inhibitory effects on CAR T cell 
proliferation and cytotoxic activity suggesting that combinatorial strategies involving CAR T 
cells and kinase inhibitors with broad targeted specificity should be carefully investigated 
preclinically to avoid any deleterious effects on CAR T cells(53). T cells can also be directly 
engineered to target the tumor vasculature via targeting of the VEGF receptors(54). A phase 
I/II clinical study (NCT01218867) targeting VEGFR2 via CAR T cells in patients with 
metastatic solid tumors has been conducted at National Cancer Institute. Treatment was well 
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tolerated and even if no significant antitumor responses were observed, the study paves the 
possibility to develop a dual targeting strategy attacking both tumor vasculature and tumor 
cells.
Enhance trafficking of CAR T cells at the tumor site
CAR T cells show homing to lymphoid tissues upon intravenous infusion in patients with B 
cell malignancies, while trafficking outside the lymphatic system and into solid tumors 
remains suboptimal. Several strategies are currently under investigation in the effort to 
induce an effective trafficking of CAR T cells at the tumor site (Figure 1, panel C). 
Classical cytotoxic drugs can have different immunomodulatory effects, and the choice of 
the right combination of cytotoxic drugs to be used within the lymphodepletion regimen 
prior to CAR T cell administration may promote CAR T cell trafficking(55). Doxorubicin 
and IL12 showed synergistic effects in promoting tumor homing of TILs in a xenograft 
mouse model of melanoma(56). Combination of doxorubicin and IL12 induces the release of 
the chemokines CXCL9 and CXCL10 binding to the receptor CXCR3, which is highly 
expressed in T cells, promote their migration to the tumor site. As alternative to 
chemotherapy, other biological agents can be used to alter the TME to support a more 
favorable milieu to T cell trafficking and persistence.
Oncolytic viruses selectively infect, lyse and replicate in malignant cells, whilst leaving non-
malignant cells unaffected(57). These viruses thus represent an appealing platform to 
promote CAR T cell migration and survival within the TME(58). Similarly, physical 
modifications of the tumor architecture that can be caused by local mild hyperthermia can 
promote the recruitment and effector function of CAR T cells(59). It is also possible to 
engineer CAR T cells to express the receptors of chemokines that are highly expressed by 
tumor cells. For example, some tumor cells produce the chemokine CCL2, but its receptor 
CCR2 is expressed at low levels on ex vivo expanded T cells. Promoting the expression of 
CCR2b in CAR T cells have been demonstrated to increase the trafficking of CAR T cells to 
the tumor(60). Finally, after ex vivo manipulation, CAR T cells also show reduced ability of 
degrading the extracellular matrix due to the lack of expression of heparanase, an enzyme 
that degrades the heparan sulfate proteoglycans. CAR T cells engineered to re-express 
heparanase effectively degrade the extracellular matrix, infiltrate the tumor and exert more 
profound antitumor activity(61).
The field of CAR engineering has been so far dominated by the expression of CARs in 
activated T lymphocytes, but other cell subsets can be redirected against tumor cells via 
CAR gene transfer. In particular for the clinical setting of solid tumors, natural killer (NK) 
cells and classical natural killer T (NKT) cells, also known as invariant NKTs, possess 
unique properties such as such as enhanced trafficking at the tumor site and CD1d restricted 
cytotoxic activity for NKT cells and innate cytotoxicity activity against tumor cells for NK 
cells. Both NK cells and NKTs can be genetically manipulated to express CARs and acquire 
antigen specificity, while maintaining their innate properties(62,63). Phase I clinical studies 
with CAR-engineered NKTs or NK cells are currently ongoing (NCT03294954, 
NCT03579927, NCT03056339).
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COPING WITH THE TUMOR MICROENVIRONMENT
The TME is a complex network that comprehends the extracellular matrix and several non-
malignant cells such as fibroblasts, macrophages and myeloid-derived suppressor cells 
(MDSCs) that contribute to tumor progression and immune evasion (Figure 2). The 
expression of inhibitory molecules, also known as inhibitory immune checkpoints, by tumor 
and stromal cells is one of the most important mechanisms impairing T cell effector 
function. The neutralization of inhibitory immune checkpoints can be carried out by either 
combining CAR T cells with the systemic administration of immune checkpoint inhibitors 
or knocking down inhibitor receptors such as PD1 in CAR T cells(64,65). Both strategies are 
currently under clinical investigation, and at the moment it is difficult to anticipate if 
selective blockade of inhibitory immune checkpoints in CAR T cells achieved by knocking 
down of PD1 is advantageous as compared to a more generalized blockade effect achieved 
with the systemic administration of immune checkpoint inhibitors. An alternative strategy to 
counteract the PD1/PD-L1 axis is to revert the inhibitory signal of PD1 in T cells coupling 
PD1 extracellular domain with the signaling domain of costimulatory molecules such as 
CD28(66). Phase I clinical trials with CRISPR-Cas9 mediated PD1 gene-knockdown in anti-
mesothelin CAR T cells or with a combination of anti-mesothelin CAR T cells and 
pembrolizumab are actually ongoing (NCT03545815, NCT02414269), as well as phase I 
studies with CAR T cells administered in combination with nivolumab alone or with 
nivolumab and ipilimumab in patients with glioblastoma (NCT04003649, NCT03726515).
Physiologically, the interaction between the receptor Fas (CD95) on T cells and its ligand 
FasL (CD95L) represents an immune homeostasis mechanism rapidly leading to T cell 
apoptotic death. FasL can be overexpressed in the TME as an immune-escape mechanism 
and the disruption of the Fas/FasL pathway by engineering CAR T cells to express a 
dominant negative receptor, as well as by Fas knockdown, showed promising results in pre-
clinical models(67,68).
One of the main soluble inhibitory factors within the TME is the transforming growth factor-
β (TGF-β), produced by cancer cells as well as by regulatory T cells (Tregs), fibroblasts, 
macrophages and platelets that inhibits T cell proliferation and effector function. TGF-β 
signaling in T cells can be blocked by engineering T cells to express a dominant-negative 
TGF-β receptor and this strategy has been already safely tested in a clinical study using 
virus specific T cells(69). A similar approach can be applied to CAR T cells and is actually 
under clinical investigations in patients with metastatic prostate cancer using anti-PSMA 
CAR T cells (NCT03089203).
The TME is also characterized by nutrient deprivation and the presence of catabolites that 
impair persistence and effector function of T cells. Metabolic reprogramming is emerging as 
a strategy to enhance the functionality of CAR T cells within the metabolically disrupted 
TME of solid tumors, and genetic manipulations of glucose or acetate metabolisms in 
adoptively transferred T cells showed promising results in preclinical models(70,71).
Among the immunosuppressive catabolites that are enriched in the TME, adenosine has 
been well characterized. Adenosine inhibits effector functions by engaging the cell-surface 
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receptor A2AR in T cells. A2AR blockade showed the potential to profoundly increase CAR 
T cell efficacy in mouse models of HER2+ solid tumors, particularly when combined with 
PD-1 blockade(72).
Cellular components of the TME such as MDSCs are considered major players in hampering 
immune responses. Depleting MDSCs with a nanoformulation of auroyl-modified 
gemcitabine improved CAR T cell efficacy in pre-clinical models of solid tumors(73). 
MDSCs can also be effectively targeted by blocking GM-CSF, and the combination of anti-
GM-CSF agents with anti-CEA CAR T cells was effective in a mouse model of colorectal 
cancer with liver metastases(74). Engineering T cells to release cytokines that reshape the 
TME, such as IL12 may reduce the inhibitory effects of M2-type tumor-associated 
macrophages and Tregs. Unfortunately, clinical experience with TILs engineered to express 
IL12 in response to NFAT in melanoma patients did not prevent the occurrence of the toxic 
effects caused by IL12 in human subjects(75). However, a clinical trial with anti-MUC16 
CAR T cells engineered to secrete IL-12 is currently ongoing in patients with MUC16-
positive solid tumors (NCT02498912).
Cytokine such as IL15 that do not have direct effects on the TME may however play a 
critical role in sustaining expansion, survival and function of CAR T cells and partially 
compensate the inhibitory effects of the TME(76). IL-15 expressing CAR T cells are 
currently under investigation in patients with liver cancer targeting glypican-3 
(NCT04093648) and in patients with neuroblastoma targeting GD2 (NCT03721068).
CONCLUSION
Targeting solid tumors with CAR T cells in the clinical setting remains challenging. Since its 
first conception in late eighties, the strategy of using chimeric molecules as functional 
receptors with antibody-type specificity to arm T cells against solid tumors has clearly 
evolved. Nowadays CAR T cell-based therapy encompasses sophisticated genetic 
engineering techniques and combinatorial approaches to counteract biological barriers, 
tumor heterogeneity and immunosuppressive properties of the TME. Nevertheless, further 
hypothesis-driven research is needed to speed up the preclinical development and fill the gap 
in the clinic between CAR T cell-based treatment in hematological malignancies and solid 
tumors. Moreover, new strategies are rapidly emerging for the redirection of T cells against 
solid tumors with the premise of a better safety profile, as in the case of CD3-bispecific 
engagers (BiTEs) that allow cytotoxic killing of tumor cells by patients T cells without ex-
vivo manipulation(77). Optimal strategies to pursue among TILs, CAR T cells and BiTEs 
are likely to be tailored to different clinical settings and tumor types.
As outlined in this review article, only translational, cooperative and interdisciplinary efforts 
including clinical oncologists, immunologists and biomedical engineers would succeed in 
decoding and effectively implement strategies to address the complex pathophysiology of 
solid tumors and immune surveillance.
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Figure 1. Strategies to overcome physical barriers in solid tumors.
Local T cell delivery can maximize the accumulation of CAR T cells at the tumor site and 
may also improve the safety profile (panel A). Biomaterials can be used to enhance the 
persistence and functionality of locally delivered CAR T cells (panel B). CAR T cells can 
be combined with antiangiogenic drugs in the effort of normalizing the intratumoral blood 
flow or with immunomodulating agents or engineered with cytokine receptors to enhance 
the trafficking (panel C).
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Figure 2. Strategies to counteract the immune suppressive tumor microenvironment.
Neutralization of inhibitory mechanisms can be carried out by either knocking down specific 
receptors in CAR T cells such as PD1 or Fas, by engineering CAR T cells to express 
dominant negative receptors (DNRs) and by combining CAR T cells with the systemic 
administration or transgenic production of immune checkpoint inhibitors (panel A). Other 
strategy to overcome the immune suppressive tumor microenvironment consist in myeloid-
derived suppressor cell (MDSCs) depletion, metabolic reprogramming of CAR T cells and 
transgenic cytokine production (panel B).
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Table 1.
Key features of TILs versus CAR T cells for adoptive cell therapy in solid tumors.
Green background indicates the strengths whereas red background indicates the weaknesses of the two 
immunotherapy approaches.
TILs CAR T cells
Difficult manufacturing (insufficient availability of tumor tissue or 
modest T cell tumor infiltration) Easy manufacturing regardless of tumor localization and tumor burden
Invasive surgical procedures to obtain tumor tissue for T cell 
isolation Non-invasive procedures (leukapheresis) for T cell isolation
Long selection and expansion process that can lead to T cell 
exhaustion Relatively short manufacturing process
Lack of T cell costimulation T cell costimulation is engineered within the CAR in second and third generation molecules
Autologous use only Possible engineering strategies to produce “off-the-shelf” T cell products
HLA-restricted recognition of the tumor cells that can lead to tumor 
escape (e.g. alteration in antigen processing and presenting 
mechanisms in tumor cells, HLA downregulation)
Recognize antigens in HLA-unrestricted manner
Can target both surface and intracellular antigens Can only target surface antigens, even if scFvs targeting peptide presented in the MHC have been developed
Can provide simultaneously multiple target specificity Up-to-now it is not feasible to target more than two antigens simultaneously
No on-target toxicity Possible on-target but off-tumor toxicity
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